Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial

PURPOSE: Both immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor (VEGFR) inhibitors are approved for advanced renal cell carcinoma treatment and can cause cardiovascular events (CVs); thus, combination therapy could lead to major adverse CV events (MACE). Cardiac ser...

Descripción completa

Detalles Bibliográficos
Autores principales: Rini, Brian I., Moslehi, Javid J., Bonaca, Marc, Schmidinger, Manuela, Albiges, Laurence, Choueiri, Toni K., Motzer, Robert J., Atkins, Michael B., Haanen, John, Mariani, Mariangela, Wang, Jing, Hariharan, Subramanian, Larkin, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177241/
https://www.ncbi.nlm.nih.gov/pubmed/35239416
http://dx.doi.org/10.1200/JCO.21.01806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177241/
https://www.ncbi.nlm.nih.gov/pubmed/35239416
http://dx.doi.org/10.1200/JCO.21.01806

Ejemplares similares